Skip to main content
Atrás
Watch Compare

PLUS THERAPEUTICS, INC.

Calidad de datos: 100%
PSTV
Nasdaq Manufacturing Measuring & Analyzing Instruments
$4.80
▲ $0.88 (22.45%)
Cap. Mercado: 26.21 M
Precio
$3.82
Cap. Mercado
26.21 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

Negative free cash flow of -20.84 M
Capital efficient — spends only 1.29% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)-10.49%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-553.56%
Below sector avg (-53.47%)
ROIC-298.85%
Net Margin-429.43%
Op. Margin-293.46%

Seguridad

Debt / Equity
N/A
Current Ratio1.29
Interest Coverage-27.92

Valoración

PE (TTM)
-1.17
Above sector avg (-1.48)
P/B Ratio5.19
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -1.2 -1.5
P/B 5.2 1.6
ROE % -553.6 -53.5
Net Margin % -429.4 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Precio Objetivo de Analistas

4 analistas
Buy
Actual
$4.80
+2827.1%
Objetivo
$140.50
$12.00
$37.50
$475.00
Pronóstico
P/E Futuro -2.04
EPS Futuro -$2.36
Ingresos Est. 23.64 M

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$2.36
-$2.69 – -$2.00
 23.64 M 4
FY2026 -$3.82
-$4.50 – -$3.46
 6.23 M 4

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.92 $0.00 +100.0%
Q32025 -$0.88 -$1.00 -14.3%
Q22025 -$3.25 -$0.16 +95.0%
Q12025 -$7.33 -$14.17 -93.3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -10.49% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5.21 M Net Income (TTM) -22.39 M
ROE -553.56% ROA -154.28%
Gross Margin N/A Operating Margin -293.46%
Net Margin -429.43% Free Cash Flow (TTM) -20.84 M
ROIC -298.85% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.29
Interest Coverage -27.92 Asset Turnover 0.36
Working Capital 3.97 M Tangible Book Value 4.68 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.17 Forward P/E N/A
P/B Ratio 5.19 P/S Ratio 5.03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -79.51%
Market Cap 26.21 M Enterprise Value 12.92 M
Per Share
EPS (Diluted TTM) -0.29 Revenue / Share 0.76
FCF / Share -3.04 OCF / Share -3.03
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 1.29% FCF Conversion 93.10%
SBC-Adj. FCF -21.79 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5.21 M 5.82 M — — —
Net Income -22.39 M -12.98 M -13.32 M -20.28 M -13.40 M
EPS (Diluted) -0.29 -2.34 -4.24 -0.77 —
Gross Profit — — — — —
Operating Income -15.30 M -14.70 M -13.32 M -19.71 M -12.49 M
EBITDA — — — — —
R&D Expenses 8.38 M 10.58 M 9.69 M — —
SG&A Expenses — — — — —
D&A 445,000.0 723,000.0 628,000.0 619,000.0 395,000.0
Interest Expense 548,000.0 179,000.0 395,000.0 711,000.0 932,000.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 16.33 M 6.63 M 11.39 M 23.87 M 21.98 M
Total Liabilities 12.33 M 15.58 M 12.74 M 17.42 M 11.15 M
Shareholders' Equity 4.00 M -8.95 M -1.35 M 6.45 M 10.84 M
Total Debt — — 3.79 M 3.79 M 5.01 M
Cash & Equivalents 4.26 M 76,000.0 8.55 M 18.12 M 18.40 M
Current Assets 15.17 M 5.26 M 9.83 M 21.82 M 19.72 M
Current Liabilities 12.31 M 15.55 M 10.73 M 11.85 M 5.87 M